Technical Analysis for ELOX - Eloxx Pharmaceuticals, Inc.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Down | Down | Down |
Historical ELOX trend table... |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | 0.00% | |
Stochastic Buy Signal | Bullish | 0.00% | |
Inside Day | Range Contraction | 0.00% | |
Wide Bands | Range Expansion | 0.00% | |
Oversold Stochastic | Weakness | 0.00% | |
Jack-in-the-Box Bearish | Bearish Swing Setup | 5.34% | |
Inside Day | Range Contraction | 5.34% | |
Wide Bands | Range Expansion | 5.34% | |
Down 3 Days in a Row | Weakness | 5.34% | |
Down 4 Days in a Row | Weakness | 5.34% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
Alert | Time |
---|---|
Up 5% | about 13 hours ago |
Up 3% | about 15 hours ago |
Up 2% | about 17 hours ago |
Up 1% | about 17 hours ago |
60 Minute Opening Range Breakout | 1 day ago |
Get a Trading Assistant
- Earnings date: 03/11/2021
Eloxx Pharmaceuticals, Inc. Description
Eloxx Pharmaceuticals, Inc. (ELOX) is a clinical-stage biopharmaceutical company developing novel RNA-modulating drug candidates that are designed to treat rare and ultra-rare premature stop codon diseases. Premature stop codons are point mutations that disrupt protein synthesis from messenger RNA. As a consequence, patients with premature stop codon diseases have reduced or eliminated protein production from the mutation bearing allele accounting for some of the most severe phenotypes in these genetic diseases. These premature stop codons have been identified in over 1,800 rare and ultra-rare diseases. Read-through therapeutic development is focused on extending mRNA half-life and increasing protein synthesis by enabling the cytoplasmic ribosome to read through premature stop codons to produce full-length proteins. Eloxx’s lead product candidate, ELX-02, is a small molecule drug candidate designed to restore production of full-length functional proteins. ELX-02 is in the early stages of clinical development focusing on cystic fibrosis and cystinosis. ELX-02 is an investigational drug that has not been approved by any global regulatory body. Eloxx is headquartered in Waltham, MA, with R&D operations in Rehovot, Israel.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Biology Clinical Development Rare Diseases Genetics Molecular Biology Gene Expression Genetic Disease Cystic Fibrosis Genetic Diseases Messenger RNA Molecular Genetics Rehovot Rare And Ultra Rare Diseases
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 6.77 |
52 Week Low | 1.98 |
Average Volume | 104,868 |
200-Day Moving Average | 3.27 |
50-Day Moving Average | 3.61 |
20-Day Moving Average | 3.16 |
10-Day Moving Average | 2.99 |
Average True Range | 0.32 |
ADX | 15.51 |
+DI | 15.52 |
-DI | 22.50 |
Chandelier Exit (Long, 3 ATRs ) | 3.15 |
Chandelier Exit (Short, 3 ATRs ) | 3.51 |
Upper Bollinger Band | 3.78 |
Lower Bollinger Band | 2.54 |
Percent B (%b) | 0.18 |
BandWidth | 38.99 |
MACD Line | -0.26 |
MACD Signal Line | -0.21 |
MACD Histogram | -0.0425 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 3.09 | ||||
Resistance 3 (R3) | 3.08 | 2.95 | 3.04 | ||
Resistance 2 (R2) | 2.95 | 2.87 | 2.96 | 3.02 | |
Resistance 1 (R1) | 2.86 | 2.82 | 2.91 | 2.87 | 3.00 |
Pivot Point | 2.73 | 2.73 | 2.76 | 2.74 | 2.73 |
Support 1 (S1) | 2.64 | 2.65 | 2.69 | 2.65 | 2.52 |
Support 2 (S2) | 2.51 | 2.60 | 2.52 | 2.50 | |
Support 3 (S3) | 2.42 | 2.51 | 2.49 | ||
Support 4 (S4) | 2.43 |